|
Phase 1-2a Study of TLK199 HCl Liposomes for Injection in Myelodysplastic Syndrome Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified health advice, travels to or treatment by using a genuine physician. We are not physicians. Always consult your dr. on Phase 1-2a Study of TLK199 HCl Liposomes for Injection in Myelodysplastic Syndrome conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Phase 1-2a Study of TLK199 HCl Liposomes for Injection in Myelodysplastic Syndrome Clinical research trials and Phase 1-2a Study of TLK199 HCl Liposomes for Injection in Myelodysplastic Syndrome health trials occur in hundreds of cities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new drugs. The propose of the studies / undertakings is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Phase 1-2a Study of TLK199 HCl Liposomes for Injection in Myelodysplastic Syndrome. Phase 1-2a Study of TLK199 HCl Liposomes for Injection in Myelodysplastic Syndrome Clinical Trials and other clinical trials permit volunteers to acquire medical treatment choices before they are available to the masses. Some times the test subjects obtain professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Phase 1-2a Study of TLK199 HCl Liposomes for Injection in Myelodysplastic Syndrome clinical trial. Participants oftentimes recieve the most expert healthcare available for their Phase 1-2a Study of TLK199 HCl Liposomes for Injection in Myelodysplastic Syndrome condition. Hazards are a reality, however, and can include extra or frequent physician visits, health risks (potentially life-endangering), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Phase 1-2a Study of TLK199 HCl Liposomes for Injection in Myelodysplastic Syndrome  Phase 1-2a Study of TLK199 HCl Liposomes for Injection in Myelodysplastic Syndrome
Phase 1-2a Study of TLK199 HCl Liposomes for Injection in Myelodysplastic Syndrome
For Condition: Myelodysplastic Syndromes
Status: Recruiting
Sponsor(s): Telik ,
Synopsis: The purpose of this study is to determine the safety and efficacy of TLK199 in patients with myelodysplastic syndrome
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Histologically or cytologically confirmed diagnosis of MDS - Adequate liver and kidney function - Ineligible for, or refusing, allogeneic bone marrow transplant - At least 18 years of age - Discontinuation of growth factors (e.g., G- CSF) at least 2 weeks prior to study entry Exclusion Criteria: - Pregnant or lactating women - History of allergy to eggs - Other investigational drugs with 14 days of study entry - Chemotherapy, radiotherapy or immunotherapy within 14 days of study entry - Concomitant steroids or hormones for the treatment of neoplasms
Total Enrollment: 51
Location and Contact Information:
University of Texas Health Science Center at San Antonio *Recruiting*
San Antonio, Texas, 78229
United States
Recruiting Sydney Rodriguez 210-617-5300
Cancer Institute Medical Group *Recruiting*
Los Angeles, California, 90025
United States
Recruiting Laura Wiggins 310-231-2182
M.D. Anderson Cancer Center *Recruiting*
Houston, Texas, 77030
United States
Recruiting Jackie Fiorentino 713-563-1688
University of Alabama at Birmingham *Recruiting*
Birmingham, Alabama, 35294
United States
Recruiting Lynda Leo 204-975-9481
Additional Information:
Study ID Numbers: TLK199.1001;
Study Start Date: April 2002
Record last reviewed: January 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00035867
Other Myelodysplastic Syndromes Studies:
1. Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
2. Safety and Efficacy of Hum195/rGel in Patients with Advanced Myeloid Malignancies
3. Interleukin-2 in Treating Patients With Myelodysplastic Syndrome
4. Genetic Study of Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes
5. Safety and Tolerability Study of FPTI in Patients With Leukemia
Related Studies:
Other Myelodysplastic Syndromes Clinical Trials
Other Texas Clinical Trials
Other San Antonio Clinical Trials
Phase 1-2a Study of TLK199 HCl Liposomes for Injection in Myelodysplastic Syndrome
|
|
|
|
|
|
|
|
